Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity

Journal of Virology

Volumn 89, Issue 13, 2015, Pages 6685-6694

  Liu, Li ^a,c   Patel, Bhavik ^a   Ghanem, Mustafa H ^a   Bundoc, Virgilio ^a   Zheng, Zhili ^b   Morgan, Richard A ^b,d   Rosenberg, Steven A ^b   Dey, Barna ^a   Berger, Edward A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Institute for Translational Medicine and Therapeutics   (United States)

^d BLUEBIRD BIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 10 17B CHIMERIC ANTIGEN RECEPTOR; CD4 35 17B CHIMERIC ANTIGEN RECEPTOR; CD4 CHIMERIC ANTIGEN RECEPTOR; CHIMERIC ANTIGEN RECEPTOR; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN BINDING; VIRUS RECEPTOR;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DESIGN; DRUG POTENCY; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION SENSITIVITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR BINDING; T LYMPHOCYTE; TARGET CELL; VIROGENESIS; VIRUS ENTRY; VIRUS INHIBITION; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; PROTEIN BINDING; RECEPTORS, ANTIGEN; RECEPTORS, HIV; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TRANSDUCTION, GENETIC;

EID: 84930896988     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00474-15     Document Type: Article

References (73)

1. Arts EJ, Hazuda DJ. 2012. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2:a007161. http://dx.doi.org/10.1101/cshperspect.a007161.
2. Nakagawa F, May M, Phillips A. 2013. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 26:17-25. http://dx.doi.org/10.1097/QCO.0b013e32835ba6b1.
3. Hatano H. 2013. Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS 8:211-216. http://dx.doi.org/10.1097/COH.0b013e32835f9788.
4. Fernandez-Montero JV, Eugenia E, Barreiro P, Labarga P, Soriano V. 2013. Antiretroviral drug-related toxicities- clinical spectrum, prevention, and management. Expert Opin Drug Saf 12:697-707. http://dx.doi .org/10.1517/14740338.2013.806480.
5. Hill AM, Cho M, Mrus JM. 2011. The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients. AIDS Rev 13:41-48.
6. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP. 2013. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 381:2109-2117. http://dx.doi.org/10.1016/S0140-6736(13)60104-X.
7. Siliciano JD, Siliciano RF. 2014. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J Allergy Clin Immunol 134:12-19. http://dx.doi.org/10.1016/j.jaci.2014.05.026.
8. Lewin SR, Deeks SG, Barre-Sinoussi F. 2014. Towards a cure for HIV- are we making progress? Lancet 384:209-211. http://dx.doi.org/10.1016/S0140-6736(14)61181-8.
9. Archin NM, Margolis DM. 2014. Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27:29-35. http://dx.doi.org/10.1097/QCO .0000000000000026.
10. Ananworanich J, Fauci AS. 2015. HIV cure research: a formidable challenge. J Virus Erad 1:1-3.
11. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E. 2009. Long-termcontrol ofHIVbyCCR5Delta32/Delta32stem-cell transplantation. N Engl J Med 360:692-698. http://dx.doi.org/10.1056/NEJMoa0802905.
12. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T. 2011. Evidence for the cure of HIV infection by CCR5 Delta 32/Delta 32 stem cell transplantation. Blood 117:2791-2799. http://dx.doi .org/10.1182/blood-2010-09-309591.
13. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group. 3 March 2013, posting date. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog http://dx.doi.org/10.1371/journal.ppat.1003211.
14. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun TW, Strain M, Richman D, Luzuriaga K. 2013. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 369:1828-1835. http://dx.doi.org/10.1056/NEJMoa1302976.
15. Ledford H. 2014. HIV rebound dashes hope of 'Mississippi baby' cure. Nature http://dx.doi.org/10.1038/nature.2014.15535.
16. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee T-H, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. 2014. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161:319-327. http://dx.doi.org/10.7326/M14-1027.
17. Kordelas L, Verheyen J, Beelen DW, Horn PA, Heinold A, Kaiser R, Trenschel R, Schadendorf D, Dittmer U, Esser S; Essen HIV AlloSCT Group. 2014. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med 371:880-882. http://dx.doi.org/10.1056/NEJMc1405805.
18. Berger EA. 2011. Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs. Curr Opin HIV AIDS 6:80-85. http://dx.doi.org/10.1097/COH .0b013e3283412515.
19. Mitsuyasu R. 2013. Curing HIV: lessons from cancer therapy. Curr Opin HIV AIDS 8:224-229. http://dx.doi.org/10.1097/COH.0b013e32835ef0a1.
20. Eshhar Z. 2010. Adoptive cancer immunotherapy using genetically engineered designer T-cells: first steps into the clinic. Curr Opin Mol Ther 12:55-63.
21. Sadelain M, Brentjens R, Riviere I. 2013. The basic principles of chimeric antigen receptor design. Cancer Discov 3:388-398. http://dx.doi.org/10.1158/2159-8290.CD-12-0548.
22. Kershaw MH, Westwood JA, Darcy PK. 2013. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525-541. http://dx.doi.org/10.1038/nrc3565.
23. Dotti G, Gottschalk S, Savoldo B, Brenner MK. 2014. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107-126. http://dx.doi.org/10.1111/imr.12131.
24. Maus MV, Grupp SA, Porter DL, June CH. 2014. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123: 2625-2635. http://dx.doi.org/10.1182/blood-2013-11-492231.
25. Hinrichs CS, Rosenberg SA. 2014. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257:56-71. http://dx.doi .org/10.1111/imr.12132.
26. Jensen MC, Riddell SR. 2014. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 257:127-144. http://dx.doi.org/10.1111/imr.12139.
27. Morgan RA, Kakarla S. 2014. Genetic modification of T cells. Cancer J 20:145-150. http://dx.doi.org/10.1097/PPO.0000000000000033.
28. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DAN, Lanier BJ, Morgan RA, Rosenberg SA. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099-4102. http://dx.doi.org/10.1182/blood-2010-04-281931.
29. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733. http://dx.doi.org/10.1056/NEJMoa1103849.
30. Couzin-Frankel J. 2013. Cancer immunotherapy. Science 342:1432-1433. http://dx.doi.org/10.1126/science.342.6165.1432.
31. Bitton N, Debre P, Eshhar Z, Gorochov G. 2001. T-bodies as antiviral agents. Curr Top Microbiol Immunol 260:271-300.
32. Lam S, Bollard C. 2013. T-cell therapies for HIV. Immunotherapy 5:407-414. http://dx.doi.org/10.2217/imt.13.23.
33. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. 2014. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 32: 189-225. http://dx.doi.org/10.1146/annurev-immunol-032713-120136.
34. Zhen A, Kitchen S. 2013. Stem-cell-based gene therapy for HIV infection. Viruses 6:1-12. http://dx.doi.org/10.3390/v6010001.
35. Roberts MR, Qin L, Zhang DZ, Smith DH, Tran AC, Dull TJ, Groopman JE, Capon DJ, Byrn RA, Finer MH. 1994. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84:2878-2889.
36. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD. 1997. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A 94:11478-11483. http://dx.doi.org/10.1073/pnas.94.21.11478.
37. Bitton N, Verrier F, Debre P, Gorochov G. 1998. Characterization of T cellexpressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J Immunol 28:4177-4187. http://dx.doi.org/10.1002/(SICI)1521-4141(199812)28:124177::AID-IMMU4177_3.0.CO;2-J.
38. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, Gennari F, Siccardi A, Marasco WA, Palu G, Parolin C. 2005. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Therapy 12:299-310. http://dx.doi.org/10.1038/sj.gt .3302413.
39. Romeo C, Seed B. 1991. Cellular immunity to HIV activated by CD4 fused to T-cell or Fc receptor polypeptides. Cell 64:1037-1046. http://dx .doi.org/10.1016/0092-8674(91)90327-U.
40. Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. 2013. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 446:268-275. http://dx.doi.org/10.1016/j .virol.2013.08.002.
41. Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. 2014. Expression of chimeric receptor CD4 zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells 32:1021-1031. http://dx .doi.org/10.1002/stem.1611.
42. MacLean AG, Walker E, Sahu GK, Skowron G, Marx P, von Laer D, Junghans RP, Braun SE. 2014. A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol 43: 341-348. http://dx.doi.org/10.1111/jmp.12137.
43. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM. 2000. Prolonged survival and tissue trafficking following adoptive transfer of CD4 zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96:785-793.
44. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC. 2000. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467-474.
45. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Haung C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM. 2002. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:788-797. http://dx.doi.org/10.1006/mthe.2002.0611.
46. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH. 2012. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4:132ra53. http://dx.doi.org/10.1126/scitranslmed .3003761.
47. Hombach AA, Holzinger A, Abken H. 2013. The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells. Curr Mol Med 13:1079-1088. http://dx.doi .org/10.2174/1566524011313070003.
48. Daar ES, Li XL, Moudgil T, Ho DD. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A 87:6574-6578. http://dx.doi.org/10.1073/pnas.87.17.6574.
49. Moore JP, McKeating JA, Huang Y, Ashkenazi A, Ho DD. 1992. Virions of primary human immunodeficiency virus type-1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 66:235-243.
50. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC. 2004. CD4(+) T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749-759. http://dx.doi.org/10.1084/jem.20040874.
51. Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan APO, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW. 2007. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog 3:e117. http://dx.doi.org/10.1371/journal.ppat.0030117.
52. Pitts TW, Bohanon MJ, Leach MF, McQuade TJ, Marschke CK, Merritt JA, Wierenga W, Nicholas JA. 1991. Soluble CD4-PE40 is cytotoxic for a transfected mammalian cell line stably expressing the envelope protein of human immunodeficiency virus (HIV-1), and cytotoxicity is variably inhibited by the sera of HIV-1-infected patients. AIDS Res Hum Retroviruses 7:741-750. http://dx.doi.org/10.1089/aid.1991.7.741.
53. Herschhorn A, Finzi A, Jones DM, Courter JR, Sugawara A, Smith AB, Sodroski JG. 1 November 2011, posting date. An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors. PLOs One http://dx.doi.org/10.1371/journal.pone .0026731.
54. Hughes MS, Yu YYL, Dudley ME, Zheng ZL, Robbins PF, Li Y, Wunderlich J, Hawley RG, Moayeri M, Rosenberg SA, Morgan RA. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. HumGene Ther 16:457-472. http://dx.doi.org/10.1089/hum.2005.16.457.
55. Morgan RA, Johnson LA, Davis JL, Zheng ZL, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA. 2012. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23:1043-1053. http://dx.doi.org/10.1089/hum.2012.041.
56. Kochenderfer JN, Feldman SA, Zhao YB, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. 2009. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32:689-702. http://dx.doi.org/10.1097/CJI.0b013e3181ac6138.
57. Liu L, Cimbro R, Lusso P, Berger EA. 2011. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A 108:20148 -20153. http://dx.doi.org/10.1073/pnas.1104840108.
58. Dey B, Del Castillo CS, Berger EA. 2003. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 77:2859-2865. http://dx.doi.org/10.1128/JVI.77.5.2859-2865.2003.
59. Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA. 2010. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 7:11. http://dx.doi.org/10.1186/1742-4690-7-11.
60. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. http://dx.doi.org/10.1038/31405.
61. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 2000. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8:1329-1339. http://dx.doi.org/10.1016/S0969-2126(00)00547-5.
62. Wiman K, Andersson M, Rask L, Peterson PA. 1982. Class-Ii antigens coded for by more than one locus are expressed in Raji cells. Scand J Immunol 16:448-448.
63. Harrison SC. 1993. CD4-structure and interactions of an immunoglobulin superfamily adhesion molecule. Accounts Chem Res 26:449-453. http://dx.doi.org/10.1021/ar00032a009.
64. Jenkins MR, Griffiths GM. 2010. The synapse and cytolytic machinery of cytotoxic T cells. Curr Opin Immunol 22:308-313. http://dx.doi.org/10.1016/j.coi.2010.02.008.
65. Schiffner T, Sattentau QJ, Duncan CJA. 2013. Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine 31:5789-5797. http://dx.doi.org/10.1016/j.vaccine.2013.10.020.
66. Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, Oosterwijk E, Sleijfer S, Debets R, Gratama JW. 2011. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117:72-82. http://dx.doi.org/10.1182/blood-2010-07-294520.
67. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. 2013. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1:26-31. http://dx.doi.org/10.1158/2326-6066.CIR-13-0006.
68. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148-151. http://dx.doi.org/10.1038/375148a0.
69. Valitutti S. 2012. The serial engagement model 17 years after: from TCR triggering to immunotherapy. Front Immunol 3:272. http://dx.doi.org/10.3389/fimmu.2012.00272.
70. Huang J, Meyer C, Zhu C. 2012. T cell antigen recognition at the cell membrane. Mole Immunol 52:155-164. http://dx.doi.org/10.1016/j .molimm.2012.05.004.
71. Eshhar Z. 1997. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 45:131-136. http://dx.doi.org/10.1007/s002620050415.
72. Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D. 2007. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother 30:684-693. http://dx.doi.org/10.1097/CJI.0b013e3180de5d90.
73. Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, Strauss H, Reiter Y. 31 October 2014. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol http://dx.doi.org/10.4049/jimmunol.1301769.